AVTR vs. TECH: Avantor vs. Bio-Techne Stock Comparison
How do Avantor (AVTR) and Bio-Techne (TECH) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Avantor (AVTR) and Bio-Techne (TECH) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
| Profile Item | AVTR | TECH |
|---|---|---|
| Name | Avantor, Inc. | Bio-Techne Corp. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 10.48 billion USD | 11.43 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | May 17, 2019 | February 9, 1989 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | AVTR | TECH |
|---|---|---|
| Total Return (1Y) | 36.41% | 27.56% |
| Total Return (3Y, Annualized) | -5.02% | 9.11% |
| Total Return (5Y, Annualized) | -16.62% | -9.91% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | AVTR | TECH |
|---|---|---|
| Volatility (1Y, Annualized) | 43.39% | 43.08% |
| Beta (5Y) | 0.94 | 1.26 |
| Max Drawdown (5Y) | -82.42% | -65.87% |
| Avg. Volume (3M) | 8.56M | 2.81M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | AVTR | TECH |
|---|---|---|
| Sharpe Ratio (1Y) | 0.74 | 0.54 |
| Sortino Ratio (1Y) | 1.17 | 0.82 |
Profitability
ROE (TTM)
Bio-Techne (TECH) at 8.33% sits in the top ROE quartile, while Avantor (AVTR) at 5.91% is closer to the peer norm — stronger capital efficiency for TECH.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.91%
- Max
- 109.18%
- Q3
- 6.23%
- AVTR
- 5.91%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
TECH
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.33%
- Max
- 109.18%
- TECH
- 8.33%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
For every dollar of sales, both Avantor (AVTR) at 5.08% and Bio-Techne (TECH) at 14.00% retain more as net profit than most peers, landing in the top net margin quartile of their industries.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.08%
- Max
- 18.05%
- AVTR
- 5.08%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
TECH
Pharmaceuticals, Biotechnology & Life Sciences industry group
14.00%
- Max
- 18.05%
- TECH
- 14.00%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Avantor (AVTR) at 8.19% and Bio-Techne (TECH) at 12.21% run core operations about as efficiently as their industries’ norm — neither stands out on operating profitability.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.19%
- Max
- 83.12%
- Q3
- 14.77%
- AVTR
- 8.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
TECH
Pharmaceuticals, Biotechnology & Life Sciences industry group
12.21%
- Max
- 83.12%
- Q3
- 14.77%
- TECH
- 12.21%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | AVTR | TECH |
|---|---|---|
| ROE (TTM) | 5.91% | 8.33% |
| ROA (TTM) | 2.83% | 6.38% |
| Net Margin (TTM) | 5.08% | 14.00% |
| Operating Margin (TTM) | 8.19% | 12.21% |
| Gross Margin (TTM) | 31.59% | 66.23% |
Growth
Revenue Growth
Bio-Techne (TECH) at -0.38% is around its peer norm for revenue growth, while Avantor (AVTR) at -3.41% drops into the bottom quartile, signaling weaker demand or pricing momentum.
EPS Growth
Bio-Techne (TECH) at 152.17% sits in the top EPS growth quartile, while Avantor (AVTR) at -175.00% is in the bottom quartile, showing a clear gap in earnings momentum.
Growth Metrics
| Metric | AVTR | TECH |
|---|---|---|
| Revenue Growth (YoY) | -3.41% | -0.38% |
| Revenue Growth (3Y CAGR) | -4.46% | 2.25% |
| EPS Growth (YoY) | -175.00% | 152.17% |
| EPS Growth (3Y CAGR) | -- | -12.97% |
Financial Strength
Current Ratio (MRQ)
Both Avantor (AVTR) at 1.89 and Bio-Techne (TECH) at 2.28 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.89
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AVTR
- 1.89
- Min
- 0.10
TECH
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.28
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- TECH
- 2.28
- Min
- 0.10
Debt / Equity (MRQ)
Both Avantor (AVTR) at 0.63 and Bio-Techne (TECH) at 0.13 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.63
- Max
- 1.42
- Q3
- 0.65
- AVTR
- 0.63
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
TECH
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.13
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- TECH
- 0.13
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | AVTR | TECH |
|---|---|---|
| Current Ratio (MRQ) | 1.89 | 2.28 |
| Debt / Equity (MRQ) | 0.63 | 0.13 |
| Net Debt / EBITDA | 3.40 | -0.20 |
Dividends
Dividend Yield (TTM)
Avantor (AVTR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bio-Techne (TECH) reports a yield of 0.44%, ranking against industry peers normally.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TECH
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.44%
- TECH
- 0.44%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Avantor (AVTR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Bio-Techne (TECH) reports a payout of 27.59%, ranking against industry peers normally.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TECH
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.59%
- TECH
- 27.59%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | AVTR | TECH |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.44% |
| Dividend Payout Ratio (TTM) | 0.00% | 27.59% |
Valuation
P/E Ratio (TTM)
Avantor (AVTR) at 30.94 is near its industry’s usual P/E ratio, while Bio-Techne (TECH) at 62.74 sits in the richer quartile — TECH needs stronger growth or earnings quality to justify the premium.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.94
- Max
- 85.34
- Q3
- 43.46
- AVTR
- 30.94
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
TECH
Pharmaceuticals, Biotechnology & Life Sciences industry group
62.74
- Max
- 85.34
- TECH
- 62.74
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Avantor (AVTR) at 1.58 sits in the cheaper P/S ratio quartile while Bio-Techne (TECH) at 9.31 prices around its industry’s middle — AVTR costs less per dollar of sales, though read it alongside growth and margins.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.58
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- AVTR
- 1.58
- Min
- 0.01
TECH
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.31
- Max
- 58.18
- Q3
- 25.77
- TECH
- 9.31
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
P/B Ratio (MRQ)
On P/B ratio, both Avantor (AVTR) at 1.80 and Bio-Techne (TECH) at 5.28 are valued close to their industries’ norm against book — neither stands out from peers.
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.80
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- AVTR
- 1.80
- Q1
- 1.69
- Min
- -5.59
TECH
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.28
- Max
- 13.53
- Q3
- 6.54
- TECH
- 5.28
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | AVTR | TECH |
|---|---|---|
| P/E Ratio (TTM) | 30.94 | 62.74 |
| P/S Ratio (TTM) | 1.58 | 9.31 |
| P/B Ratio (MRQ) | 1.80 | 5.28 |
| Free Cash Flow Yield (TTM) | 4.21% | 2.39% |